Pharmacovigilance during Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) in Routine Clinical Practice

Due to Cytochrome P450 3A (CYP3A) metabolism, clinical trials of ibrutinib-treated CLL patients prohibited concurrent medications metabolized by CYP3A. We evaluated concomitant medication use in 118 ibrutinib-treated CLL patients outside the context of clinical trials. Seventy-five (64%) patients we...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Leuk Lymphoma
Hauptverfasser: Finnes, Heidi D., Chaffee, Kari G., Call, Timothy G., Ding, Wei, Kenderian, Saad S., Bowen, Deborah A., Conte, Michael, McCullough, Kristen B., Merten, Julianna A., Bartoo, Gabriel T., Smith, Matthew D., Leis, Jose, Chanan-Khan, Asher, Schwager, Susan M., Slager, Susan L., Kay, Neil E., Shanafelt, Tait D., Parikh, Sameer A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2016
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5364094/
https://ncbi.nlm.nih.gov/pubmed/27820970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2016.1251592
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge